201 related articles for article (PubMed ID: 24034373)
1. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases.
Machet L; Samimi M; Delage M; Paintaud G; Maruani A
J Am Acad Dermatol; 2013 Oct; 69(4):649-50. PubMed ID: 24034373
[No Abstract] [Full Text] [Related]
2. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis.
Scheinfeld N
Dermatol Online J; 2013 Jun; 19(6):18558. PubMed ID: 24011308
[TBL] [Abstract][Full Text] [Related]
3. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.
De Souza A; Solomon GE; Strober BE
Bull NYU Hosp Jt Dis; 2011; 69(2):185-7. PubMed ID: 22035400
[TBL] [Abstract][Full Text] [Related]
4. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
[TBL] [Abstract][Full Text] [Related]
5. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
Vinkel C; Thomsen SF
Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for the treatment of hidradenitis suppurativa.
Lebwohl B; Sapadin AN
J Am Acad Dermatol; 2003 Nov; 49(5 Suppl):S275-6. PubMed ID: 14576652
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases.
Moschella SL
Int J Dermatol; 2007 Dec; 46(12):1287-91. PubMed ID: 18173525
[TBL] [Abstract][Full Text] [Related]
8. Association and management of Crohn's disease plus hidradenitis suppurativa.
dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
[No Abstract] [Full Text] [Related]
9. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes?
Garzorz N; Papanagiotou V; Atenhan A; Andres C; Eyerich S; Eyerich K; Ring J; Brockow K
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):141-3. PubMed ID: 25070077
[No Abstract] [Full Text] [Related]
10. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study.
Lee JH; Kwon HS; Jung HM; Kim GM; Bae JM
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1784-1790. PubMed ID: 29761904
[TBL] [Abstract][Full Text] [Related]
11. Pyoderma gangrenosum treated with infliximab in inactive ulcerative colitis.
Ermis F; Ozdil S; Akyüz F; Pinarbasi B; Mungan Z
Inflamm Bowel Dis; 2008 Nov; 14(11):1611-3. PubMed ID: 18401859
[No Abstract] [Full Text] [Related]
12. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
Groleau PF; Grossberg AL; Gaspari AA
Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa.
Fischer AH; Jourabchi N; Khalifian S; Lazarus GS
Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of hidradenitis suppurativa and inflammatory bowel disease: are these two disease associated?
Salgado-Boquete L; Romaní J; Carrión L; Marín-Jiménez I
Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():8-12. PubMed ID: 28081771
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Reddick CL; Singh MN; Chalmers RJ
Dermatol Online J; 2010 Aug; 16(8):15. PubMed ID: 20804692
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of hidradenitis suppurativa.
Fernández-Vozmediano JM; Armario-Hita JC
Dermatology; 2007; 215(1):41-4. PubMed ID: 17587838
[TBL] [Abstract][Full Text] [Related]
17. [Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature].
García-Rabasco AE; Esteve-Martínez A; Zaragoza-Ninet V; Sánchez-Carazo JL; Alegre-de-Miquel V
Actas Dermosifiliogr; 2010 Oct; 101(8):717-21. PubMed ID: 20965015
[TBL] [Abstract][Full Text] [Related]
18. Non-psoriatic dermatologic uses of monoclonal antibody therapy.
Sockolov ME; Alikhan A; Zargari O
J Dermatolog Treat; 2009; 20(6):319-27. PubMed ID: 19954387
[TBL] [Abstract][Full Text] [Related]
19. The Association between Hidradenitis Suppurativa and Crohn's Disease: in Search of the Missing Pathogenic Link.
van der Zee HH; Horvath B; Jemec GBE; Prens EP
J Invest Dermatol; 2016 Sep; 136(9):1747-1748. PubMed ID: 27542293
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease.
Rosi YL; Lowe L; Kang S
J Dermatolog Treat; 2005 Feb; 16(1):58-61. PubMed ID: 15897171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
